American Society of Clinical Oncology– tag –
-
ASCO 2026 Features AI-Augmented ctDNA Analysis for Prognostic Risk Stratification in Metastatic Clear Cell RCC, Pioneering GU Oncology Advancements
UroToday USA Overview UroToday's coverage of ASCO 2026 highlights several presentations in genitourinary oncology, prominently featuring an 'AI-Augmented Analysis of Quantitative ctDNA Burden and Longitudinal Kinetics to Identify Prognos... -
ASCO 2026 Reveals LITESPARK-022 Trial’s Significant DFS Improvement with Adjuvant Pembrolizumab Plus Belzutifan in Renal Cell Carcinoma
Oncodaily USA Overview New insights into adjuvant therapy for renal cell carcinoma (RCC) were presented at the 2026 ASCO Annual Meeting. The LITESPARK-022 trial demonstrated that adjuvant pembrolizumab combined with belzutifan significan... -
HER2-Targeted Regimen Achieves 60.2% Pathologic Complete Response Rate in Locally Advanced HER2-Positive Breast Cancer in China’s Phase II neoPICD Trial, Presented at ASCO Breakthrough 2026
The ASCO Post USA Overview A HER2-targeted regimen demonstrated a high pathologic complete response (pCR) rate of 60.2% in patients with locally advanced HER2-positive breast cancer in the phase II neoPICD trial conducted in China. Prese... -
ASCO 2026 Highlights Critical Gap in AI Education for Oncology Fellows Amidst Widespread AI Tool Adoption for Cancer Navigation
Google Cloud (CBCN Canada) USA Overview The 2026 ASCO Annual Meeting underscored the vital role of AI in empowering cancer patients and caregivers through education and advocacy. A presented study revealed that while 74% of hematology/on... -
ASCO 2026 Highlights Emergence of Pan-RAS Inhibitors and Deep Integration of AI with Liquid Biopsy in Oncology
neoag USA Overview Analysis of 7,282 abstracts presented at ASCO 2026 reveals critical trends in oncology, including the rise of pan-RAS inhibitors and the extensive integration of AI with liquid biopsy technologies. AI was cited in 12.6... -
Tempus AI and Roswell Park Unveil Groundbreaking AI Algorithms for Pancreatic Cancer and Metastatic RCC at ASCO 2026
Tempus 他 USA Overview At the 2026 ASCO Annual Meeting, Tempus AI and Roswell Park Comprehensive Cancer Center announced significant advancements in AI-driven oncology, showcasing novel algorithms designed to revolutionize cancer diagnos... -
Tempus AI Unveils Promising Initial Results from Oncology Multimodal Foundation Model Trained on 2.5M Longitudinal Records, Achieving C-index of 0.802 for OS Prediction
Business Wire USA Overview Tempus AI announced initial results at ASCO 2026 for its multimodal foundation model aimed at oncology insight generation. This transformer-based model, trained on 2.5 million longitudinal records, 450,000 digi... -
FDA-Cleared AI “Artera AI Breast” Demonstrates Clinical Utility for Breast Cancer Prognosis and Chemotherapy Benefit Prediction at ASCO 2026
The Pathologist USA Overview At ASCO 2026, a study showcased the utility of Artera AI Breast, an FDA-cleared multimodal artificial intelligence model, for predicting prognosis and chemotherapy benefit in postmenopausal women with node-po...
1